Pfizer’s Lung Cancer Drug Works in patients with Genetic defect

September 28, 2014 2:30 AM

6 0

Pfizer’s Lung Cancer Drug Works in patients with Genetic defect

The drug Pfizer Inc’s Xalkori (known chemically as crizotinib) that treats lung cancer patients with a specific gene mutation, has been proven effective in shrinking tumors in those with an even rarer form of the disease.

According to a study presented at a medical meeting this may provide the first targeted treatment for these patients.

Also read: RBS Fails Toughest-Ever BOE Stress Test, Boosts Capital Plan

Read more

To category page

Loading...